drugset
drugset / Trial / NCT05251376

Study of LYN-014 in Individuals With Opioid Use Disorder Who Are Stable on Methadone Therapy

NCT05251376 ↗

Phase 1 Withdrawn Lyndra Inc. National Institute on Drug Abuse (NIDA) · collab
NaSingle-groupOpen-labelTreatment

Summary

A Phase 1, Single Dose, Open-label, Safety, Tolerability, and Pharmacokinetic Study of LYN-014 in Individuals with Opioid Use Disorder Who are Stable on Methadone Therapy

Timeline

Start
2022-02-28
Primary completion
2022-12-19
Completion
2022-12-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Levomethadone Small molecule 187 mg Oral
Background Methadone Other / unclassified — Oral
Background Morphine Other / unclassified — —

Indications

opiate dependence